Adrance L 25mg/5mg Tablets (14s)

Description

Adrance L is a prescription combination medicine for improving blood glucose control in adults with type 2 diabetes mellitus. It combines empagliflozin, and linagliptin in an oral extended-release tablet.

• Manufacturer Name: Atco
• Drug Class: Antidiabetic combination: SGLT2 inhibitor, DPP-4 inhibitor, and biguanide
• Dosage Form:  Tablet
• Storage: Store at room temperature in a dry place, protected from heat, moisture, and direct sunlight. Keep out of reach of children.
• Pack Size: Pack of 14 Tablets

Adrance L 25mg/5mg Tablets (14s) Available Online in Pakistan

Dwatson offers Adrance L 25mg/5mg Tablets (14s) at Rs. 350, with fast, discreet delivery across Pakistan.

Ingredients

• Empagliflozin 25 mg
• Linagliptin 5 mg

Benefits

• Improves blood glucose control in adults with type 2 diabetes mellitus.
• Used alongside an appropriate diet and regular exercise.
• May be used when treatment with multiple glucose-lowering medicines is required.

Usage & Safety

For Adult

• Take exactly as prescribed by the physician, usually once daily with food.
• Swallow the tablet whole with water; do not crush, split, or chew the extended-release tablet.
• Dosage should be individualized according to blood glucose control, kidney function, tolerability, and previous diabetes treatment.
• Maintain adequate fluid intake unless fluid restriction has been advised by a healthcare professional.

For Children

• Safety and effectiveness have not been adequately established in children and adolescents under 18 years.
• Not recommended for pediatric use unless specifically prescribed by a specialist.
• No established pediatric weight-based dosing is available for this combination.

Side Effects

• Common effects may include nausea, diarrhea, abdominal discomfort, reduced appetite, increased urination, thirst, headache, and genital or urinary tract infections.
• Low blood sugar may occur, particularly when used with insulin or sulfonylureas.
• Serious reactions may include diabetic ketoacidosis, lactic acidosis, severe dehydration, acute kidney injury, pancreatitis, severe allergic reactions, and serious genital infections.

Contraindications

• Do not use in patients with hypersensitivity to empagliflozin, linagliptin, or any component of the product.
• Contraindicated in diabetic ketoacidosis, diabetic pre-coma, or type 1 diabetes mellitus.
• Do not use in severe kidney impairment or acute kidney injury.
• Avoid in severe liver impairment, severe dehydration, serious infection, shock, or conditions associated with tissue hypoxia.
• Use caution in patients with a history of pancreatitis, recurrent genital or urinary infections, low blood pressure, or heart failure.
• Metformin should generally be withheld around iodinated contrast procedures and during major surgery according to medical advice.

Precautions & Warnings

• Insulin and sulfonylureas may increase the risk of hypoglycemia.
• Diuretics and other medicines that lower blood pressure may increase dehydration or low blood pressure risk.
• Alcohol may increase the risk of lactic acidosis and abnormal blood glucose levels.
• Medicines that induce P-glycoprotein or CYP3A4, such as rifampicin, may reduce linagliptin exposure and glucose-lowering effectiveness.
• Corticosteroids, thyroid medicines, sympathomimetics, and some antipsychotics may raise blood glucose levels.

Pregnancy

• Not generally recommended during pregnancy, particularly during the second and third trimesters, unless clearly prescribed by a specialist.
• Consult a physician promptly if pregnancy occurs during treatment.
• Use during breastfeeding is generally not recommended because of potential effects on the nursing infant, including the kidneys and glucose metabolism.